Stockreport

Blueprint Medicines' Continued Leadership in Redefining the Standard of Care in Systemic Mastocytosis Highlighted at 2024 ASH Annual Meeting [Yahoo! Finance]

Blueprint Medicines Corporation  (BPMC) 
Last blueprint medicines corporation earnings: 2/13 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: blueprintmedicines.com
PDF for the treatment of indolent systemic mastocytosis (ISM). AYVAKIT is approved by the U.S. Food and Drug Administration (FDA) for the treatment of three indications: adu [Read more]